Pfizer launches Rimegepant in Singapore for Acute and Prophylactic Migraine relief

New Drug Applications |  News | 0 Comment | 31 Jan, 2024

Pfizer’s NURTEC® (rimegepant), an orally disintegrating tablet for both the acute treatment of migraine is now...Read more

Junshi Biosciences, Dr. Reddy’s to develop and commercialise oncology drug in 21 countries

New Drug Applications |  News | 3 Comment | 08 May, 2023

Shanghai Junshi Biosciences Co. has collaborated with Indian pharmaceutical firm Dr. Reddy’s Laboratories to devel...Read more

Monoclonal antibody drug by GSK Singapore approved to treat chronic rhinosinusitis

New Drug Applications |  News | 0 Comment | 07 Feb, 2023

GSK Singapore announced that Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5...Read more

China approves first and only therapy available for patients with EGFR Exon20 Insertion+ NSCLC

New Drug Applications |  News | 0 Comment | 12 Jan, 2023

Japan headquatered Takeda's EXKIVITY (mobocertinib) has been approved by the National Medical Products Administration (N...Read more

Diabetic neuropathic pain field presents significant opportunity for drug developers, says GlobalData

New Drug Applications |  Analysis | 0 Comment | 20 Dec, 2022

The current diabetic neuropathic pain treatment paradigm includes many established analgesics that provide sym...Read more

Singapore paves the way for improved treatment of Alzheimer’s disease

New Drug Applications |  News | 0 Comment | 06 Dec, 2022

A major clinical trial of an antibody treatment may soon pave the way for improved treatment of Alzheimer’s diseas...Read more

Huadong becomes strategic partner in Asia for Heidelberg Pharma, strikes deal worth $0.9B

New Drug Applications |  News | 0 Comment | 01 Mar, 2022

German firm Heidelberg Pharma AG and Huadong Medicine in China have entered into a strategic partner...Read more

Japan to commercialize next-gen Hunter Syndrome therapy

New Drug Applications |  News | 0 Comment | 01 Oct, 2021

Japanese firms Takeda Pharmaceutical Company and JCR Pharmaceuticals have announced a geographically-focused exclusive c...Read more

US approves first ophthalmology biosimilar, developed by South Korea

New Drug Applications |  News | 0 Comment | 23 Sep, 2021

South Korea-based Samsung Bioepis has announced that the US Food and Drug Administration (FDA) has approved BYOOVIZ...Read more

Japan sets eyes on rare pediatric liver diseases

New Drug Applications |  News | 0 Comment | 22 Sep, 2021

US-based Mirum Pharmaceuticals, Inc. and Japanese firm Takeda Pharmaceutical have entered into an exclusive licensing ag...Read more

Australia approves novel therapy to treat Advanced Small Cell Lung Cancer

New Drug Applications |  News | 0 Comment | 15 Sep, 2021

Australian patients with an aggressive form of lung cancer (metastatic Small Cell Lung Cancer) can now access a new...Read more

Eli Lilly Japan, Daiichi Sankyo ink pact to commercialise migraine drug

New Drug Applications |  News | 0 Comment | 01 Sep, 2021

Eli Lilly Japan and Daiichi Sankyo Company have concluded an agreement on commercialisation collaboration in Japan for t...Read more

Japan to distribute hyperuricemia drug in five ASEAN countries

New Drug Applications |  News | 0 Comment | 31 Aug, 2021

Japan-based Eisai and FUJI YAKUHIN have inked a license agreement concerning dotinurad (generic name), a treatment for h...Read more

Menarini to commercialize Japanese drug in Singapore, Malaysia, and the Philippines

New Drug Applications |  News | 0 Comment | 23 Aug, 2021

Singapore-based Menarini Asia-Pacific Holdings, a part of the leading Italian global biopharmaceutical company Menarini ...Read more

UK's NICE recommends abemaciclib for advanced breast cancer

New Drug Applications |  News | 0 Comment | 13 Aug, 2021

The UK National Institute for Health and Care Excellence (NICE) has published new draft guidance which recommends Eli Li...Read more

FDA approves combination therapy for Advanced Renal Cell Carcinoma (RCC)

New Drug Applications |  News | 0 Comment | 12 Aug, 2021

U.S. Food and Drug Administration (FDA) has approved a combination therapy from Eisai and Merck (MSD) namely,&...Read more

Yuyu Pharma to distribute Novartis Korea's prescription medicines

New Drug Applications |  News | 0 Comment | 04 Aug, 2021

Yuyu Pharma and Novartis Korea have entered into an agreement in which Yuyu will have exclusive distribution rights for ...Read more

FDA approves Medtronic's Artificial Intelligence Algorithms for Cardiac Monitoring

New Drug Applications |  News | 0 Comment | 29 Jul, 2021

Medtronic, (headquartered in Dublin, Ireland), the global leader in medical technology, announced U.S. Food and Dru...Read more